Nasdaq:IMUX
IMMUNIC, INC.
A clinical-stage immuno-oncology developer advancing novel cancer therapies through a proprietary platform while currently operating without commercial revenue generation.
Key Metrics
Investment Thesis
Bull Case
Early-stage investors may view IMUX as a high-risk, high-reward opportunity to back a proprietary immuno-oncology platform before other competitors gain market traction. If the company successfully advances its pipeline candidates through clinical trials and achieves regulatory approval, the potential upside could be substantial upon eventual commercialization. The current lack of dilution from common share issuances suggests management is preserving equity value while attempting to extend runway.
Bear Case
The stock carries extreme risk due to a negative shareholders' equity of $-6.7M and total liabilities exceeding total assets, signaling potential insolvency if funding dries up. Investors should avoid this holding given the consistent multi-year net losses without any revenue generation or path to profitability visible in current data. The company's cash burn from operations ($-85.8M) significantly outpaces its financing inflows, suggesting an unsustainable financial trajectory without immediate capital injection.
About IMMUNIC, INC.
IMMUNIC Inc. (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer, primarily leveraging its proprietary immuno-oncology platform. The company operates within the competitive oncology market, focusing on research and development to bring innovative treatments to patients with limited therapeutic options. Currently, the firm has not yet generated commercial revenue, relying entirely on capital markets and strategic financing to fund its extensive R&D pipeline.
Analysis
Management Discussion
Recent financial performance highlights a continued deep burn rate with net income remaining negative at $-97.2M for 2025, consistent with prior years ranging from $-93.6M to $-120.4M over the last five years. The company has not achieved commercialization, resulting in zero revenue and a gross profit of zero, while spending heavily on R&D ($82.0M) and share-based compensation ($8.9M). Cash balances have stabilized at $15.5M but are insufficient to cover operating deficits without external capital raises.
Industry Overview
The immuno-oncology sector is highly competitive and capital intensive, characterized by long development cycles and high failure rates for new therapies. Companies in this space typically require billions in funding to navigate clinical trials and secure regulatory approval before generating commercial sales. Market leaders often possess significant cash reserves and diversified pipelines, whereas smaller players like IMMUNIC must rely on venture capital or public markets to survive.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $119.5M | $99.2M | $98.1M | $103.2M |
| Operating Income | $-119.5M | $-99.2M | $-98.1M | $-103.2M |
| R&D | $71.3M | $83.2M | $80.0M | $82.0M |
| G&A | $15.3M | $16.0M | $18.0M | $21.2M |
| Stock-Based Comp | $7.9M | $7.1M | $8.5M | $8.9M |
| D&A | $77.0K | $111.0K | $134.0K | $168.0K |
| Other OpEx | $33.0M | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Income | $1.0M | $3.1M | $3.4M | $1.0M |
| Pre-Tax Income | $-119.5M | $-99.2M | $-98.1M | $-103.2M |
| Income Tax | $919.0K | $-5.6M | $2.5M | $0 |
| Continuing Ops | $-120.4M | $-93.6M | $-100.5M | $-103.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-120.4M | $-93.6M | $-100.5M | $-97.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-120.4M | $-93.6M | $-100.5M | $-97.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $125.9M | $52.5M | $39.3M | $22.9M |
| Cash & Equivalents | $106.7M | $46.7M | $35.7M | $15.5M |
| Prepaid Expenses | $9.5M | $5.9M | $3.7M | $7.4M |
| Other Current Assets | $9.6M | $0 | $0 | $0 |
| Long-Term Assets | $1.9M | $1.8M | $1.5M | $1.2M |
| PP&E (Net) | $294.0K | $466.0K | $545.0K | $608.0K |
| Goodwill | $0 | — | — | — |
| Operating Leases | $1.6M | $1.3M | $991.0K | $575.0K |
| Other LT Assets | $43.0K | $0 | $0 | $0 |
| Total Assets | $127.8M | $54.3M | $40.9M | $24.1M |
| Current Liabilities | $13.1M | $24.7M | $22.2M | $30.6M |
| Accounts Payable | $4.3M | $5.1M | $7.8M | $10.1M |
| Current Leases | $571.0K | $695.0K | $740.0K | $470.0K |
| Other Current Liab | $239.0K | $271.0K | $676.0K | $1.4M |
| Long-Term Liabilities | $992.0K | $639.0K | $264.0K | $107.0K |
| LT Operating Leases | $992.0K | $639.0K | $264.0K | $107.0K |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $14.1M | $25.4M | $22.4M | $30.7M |
| Shareholders' Equity | $113.7M | $28.9M | $18.4M | $-6.7M |
| Paid-In Capital | $427.9M | $436.1M | $525.6M | $599.2M |
| Retained Earnings | $-317.3M | $-410.9M | $-511.4M | $-608.6M |
| AOCI | $3.0M | $3.8M | $4.2M | $2.6M |
| Total L&E | $127.8M | $54.3M | $40.9M | $24.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-120.4M | $-93.6M | $-100.5M | $-97.2M |
| Non-Cash Adjustments | $60.7M | $15.5M | $18.9M | $3.2M |
| Working Capital Changes | $-5.5M | $7.3M | $-3.2M | $8.2M |
| Cash from Operations | $-65.1M | $-70.8M | $-84.8M | $-85.8M |
| Capital Expenditures | $112.0K | $334.0K | $264.0K | $161.0K |
| Cash from Investing | $-9.7M | $9.5M | $-264.0K | $-161.0K |
| Cash from Financing | $95.8M | $1.0M | $74.5M | $65.6M |
| FX Effect | $-993.0K | $262.0K | $-517.0K | $205.0K |
| Net Change in Cash | $19.9M | $-60.1M | $-11.0M | $-20.2M |
| Beginning Cash | $86.9M | $106.7M | $46.7M | $35.7M |
| Ending Cash | $106.7M | $46.7M | $35.7M | $15.5M |
Frequently Asked Questions
How does IMMUNIC, INC. make money?
The company's operations are concentrated in a single primary segment focused on Research & Development, specifically targeting immuno-oncology indications. This segment encompasses high-cost activities such as research and development expenses ($82.0M in the latest year) and general administrative costs, with no current commercial sales or revenue streams.
What are the main risks for IMUX?
The company faces severe liquidity risks, evidenced by negative operating cash flow of $-85.8M and a significant accumulated deficit of $-608.6M. As a pre-revenue entity, IMMUNIC is entirely dependent on continued equity financing to fund operations, creating vulnerability to market volatility. The current financial structure shows liabilities ($30.7M) exceeding assets ($24.1M), indicating potential solvency challenges if funding ceases. There is also the risk of clinical trial failure or regulatory delays which could further deplete cash reserves without revenue offsets.
What is IMUX's competitive advantage?
The company possesses a proprietary immuno-oncology platform designed to enhance T-cell function for cancer treatment. Its strategic focus on addressing unmet needs in oncology provides a specialized niche within the broader biopharmaceutical industry. The organization maintains flexibility in its development pipeline by focusing resources on high-potential candidates that can differentiate it from larger competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.